Back to Results
First PageMeta Content
Biology / Boceprevir / Gilead Sciences / Boehringer Ingelheim / Interferon / NS3 / Pharmacology / Microbiology / Protease inhibitors / Telaprevir / Hepatitis C virus


Clinical Nursing Experience with Direct Acting Antivirals (DAA’s) Montreal – Feb 24, 2012 Keri Earnshaw, RN, CCRP Jo-Ann Ford, RN, MSN BC Hepatitis Program
Add to Reading List

Document Date: 2013-10-19 18:07:33

Open Document

File Size: 2,69 MB

Share Result on Facebook

City

Montreal / Bristol / /

Company

Vertex Inc. / Celsion Corp. / Johnson & Johnson / Merck Canada / Gilead Sciences / BOC / Mitchell AE / Pfizer Canada / /

Continent

South America / AFRICA / /

Country

United States / Canada / Australia / /

Event

FDA Phase / /

IndustryTerm

HCV Therapy / protease active site / /

MedicalCondition

chronic carriers / CHC / cancer / HCV Genotype 1 / HCV / HCV hepatitis C / liver disease / HCV RNA / /

MedicalTreatment

blood transfusions / /

Organization

World Health Organization / MSN BC Hepatitis Program Diamond Centre / /

Person

Keri Earnshaw / Jo-Ann Ford / /

Product

SPRINT / PegIntron / PegIntron® / /

Region

WEST EUROPE / SOUTH EAST ASIA / EAST MEDITERRANEAN / EAST ASIA / /

Technology

Genotype / /

SocialTag